MedTrace Logo

Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

NCT04744454 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of this study is to observe safety and effectiveness of Cresemba in patients with invasive Aspergillosis or invasive Mucormycosis in Korea during the post-marketing surveillance period as required by Ministry of Food and Drug Safety (MFDS).

Conditions

  • Aspergillosis
  • Mucormycosis

Interventions

DRUG

Isauvuconazole group

Patients who are treated with Isavuconazole according to its protocol label.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-28
Primary Completion
2026-01-13
Completion
2026-01-13

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04744454 on ClinicalTrials.gov